logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug

There were no safety concerns from the first set of patients enrolled into the trial, so MaxCyte is to up the dose for those in the second cohort as planned

ovarian cancer
MCY-M11 has been developed from MaxCyte’s own CARMA cell therapy platform

MaxCyte Inc (LON:MXCT) has started dosing the second cohort of patients in the phase I clinical trial of its MCY-M11 cancer immunotherapy.

MCY-M11 is the first drug from MaxCyte’s CARMA cell therapy platform. It is being used to treat 15 women with ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

READ: MaxCyte shows off CARMA platform at Washington DC conference

The women in this second cohort will receive a higher dose of the drug than those who were part of the first wave of patients.

There were no dose-limiting toxicities or safety concerns observed in the first set of cancer sufferers, MaxCyte confirmed.

“Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform,” said chief medical officer Claudio Dansky Ullmann.

“We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options.”

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read